# Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).

Source: https://onco.cc/trials/nct05219500/  
OnCo record `nct05219500` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of FPI-2265 in prostate cancer, run by Fusion Pharmaceuticals Inc., active and no longer recruiting.

## Summary

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). is a phase 2 interventional study registered as NCT05219500 by Fusion Pharmaceuticals Inc., with 115 participants planned, started 2021-12-16 and due to reach its primary completion in 2025-05-30. Interventions recorded: FPI-2265. Conditions listed: Metastatic Castration Resistant Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05219500
- Phase: 2
- Setting: PSMA-directed Targeted Alpha Therapy With FPI-2265 (225Ac-PSMA-I&T) for the Treatment of Metastatic Castration-resISTant Prostate Cancer (TATCIST). A Phase II Clinical Trial.
- Sponsor: Fusion Pharmaceuticals Inc.
- Enrolled: 115

## Sources

- ClinicalTrials.gov NCT05219500: https://clinicaltrials.gov/study/NCT05219500

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [FPI-2265](https://onco.cc/drugs/fpi-2265/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05219500.json